These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

448 related items for PubMed ID: 21847518

  • 1. Efficacy and safety of moxifloxacin for community-acquired bacterial pneumonia based on pharmacokinetic analysis.
    Yoshida K, Okimoto N, Kishimoto M, Fukano H, Hara H, Yoneyama H, Moriya O, Kawanishi M, Kimura M, Matsushima T, Niki Y.
    J Infect Chemother; 2011 Oct; 17(5):678-85. PubMed ID: 21847518
    [Abstract] [Full Text] [Related]

  • 2. Pharmacokinetic and pharmacodynamic aspects of oral moxifloxacin 400 mg/day in elderly patients with acute exacerbation of chronic bronchitis.
    Pea F, Pavan F, Lugatti E, Dolcet F, Talmassons G, Screm MC, Furlanut M.
    Clin Pharmacokinet; 2006 Oct; 45(3):287-95. PubMed ID: 16509760
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and safety of ten day moxifloxacin 400 mg once daily in the treatment of patients with community-acquired pneumonia. Community Acquired Pneumonia Study Group.
    Patel T, Pearl J, Williams J, Haverstock D, Church D.
    Respir Med; 2000 Feb; 94(2):97-105. PubMed ID: 10714413
    [Abstract] [Full Text] [Related]

  • 4. Moxifloxacin pharmacokinetic profile and efficacy evaluation in empiric treatment of community-acquired pneumonia.
    Öbrink-Hansen K, Hardlei TF, Brock B, Jensen-Fangel S, Kragh Thomsen M, Petersen E, Kreilgaard M.
    Antimicrob Agents Chemother; 2015 Apr; 59(4):2398-404. PubMed ID: 25666151
    [Abstract] [Full Text] [Related]

  • 5. The integrated use of pharmacokinetic and pharmacodynamic models for the definition of breakpoints.
    Stass H, Dalhoff A.
    Infection; 2005 Dec; 33 Suppl 2():29-35. PubMed ID: 16518709
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Moxifloxacin in respiratory tract infections.
    Miravitlles M.
    Expert Opin Pharmacother; 2005 Feb; 6(2):283-93. PubMed ID: 15757424
    [Abstract] [Full Text] [Related]

  • 12. Assessment of different antibacterial effect measures used in in vitro models of infection and subsequent use in pharmacodynamic correlations for moxifloxacin.
    MacGowan A, Rogers C, Holt HA, Wootton M, Bowker K.
    J Antimicrob Chemother; 2000 Jul; 46(1):73-8. PubMed ID: 10882692
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Moxifloxacin, a new antibiotic designed to treat community-acquired respiratory tract infections: a review of microbiologic and pharmacokinetic-pharmacodynamic characteristics.
    Nightingale CH.
    Pharmacotherapy; 2000 Mar; 20(3):245-56. PubMed ID: 10730681
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Population pharmacokinetics and pharmacodynamics of garenoxacin in patients with community-acquired respiratory tract infections.
    Van Wart S, Phillips L, Ludwig EA, Russo R, Gajjar DA, Bello A, Ambrose PG, Costanzo C, Grasela TH, Echols R, Grasela DM.
    Antimicrob Agents Chemother; 2004 Dec; 48(12):4766-77. PubMed ID: 15561855
    [Abstract] [Full Text] [Related]

  • 18. Efficacy and safety of 3-day azithromycin versus 5-day moxifloxacin for the treatment of acute bacterial exacerbations of chronic bronchitis.
    Zervos M, Martinez FJ, Amsden GW, Rothermel CD, Treadway G.
    Int J Antimicrob Agents; 2007 Jan; 29(1):56-61. PubMed ID: 17189096
    [Abstract] [Full Text] [Related]

  • 19. Pharmacodynamics of moxifloxacin against anaerobes studied in an in vitro pharmacokinetic model.
    Noel AR, Bowker KE, Macgowan AP.
    Antimicrob Agents Chemother; 2005 Oct; 49(10):4234-9. PubMed ID: 16189103
    [Abstract] [Full Text] [Related]

  • 20. Moxifloxacin: a respiratory fluoroquinolone.
    Miravitlles M, Anzueto A.
    Expert Opin Pharmacother; 2008 Jul; 9(10):1755-72. PubMed ID: 18570608
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.